Cutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series.

Authors

Lenique Kl Huggins, Jaya Manjunath, May Alorainy, Jonathan S Leventhal, Sandhya Deverapalli

Published in

Journal of drugs in dermatology : JDD. Volume 25. Issue 7. Pages 659-660. Jul 01, 2026.

Abstract

Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting quality of life and adherence.
We report 4 cases of cutaneous toxicity from AIs or HER2-targeted agents, detailing presentation, management, and outcomes.
Three patients developed acneiform eruptions: one after starting letrozole, resolving on discontinuation, and 2 on trastuzumab/pertuzumab requiring isotretinoin after failing topical/antibiotic therapy. A fourth developed lichen planus pigmentosus six months into anastrozole chemoprevention, with limited response to topicals and treatment cessation due to psychosocial distress.
Acneiform eruptions may occur with both HER2 blockade and AIs, while pigmentary disorders may represent a novel AI toxicity. Prompt recognition and targeted care may facilitate cancer treatment continuation.  .

PMID:
42406353
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.